e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
46.94
-0.09 (-0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,216,547
Open
46.95
Bid (Size)
45.00 (100)
Ask (Size)
47.96 (100)
Prev. Close
47.03
Today's Range
46.81 - 47.54
52wk Range
29.66 - 47.86
Shares Outstanding
388,132,400
Dividend Yield
2.00%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Today 10:07 EDT
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...
Via
Finterra
Topics
Economy
Initial Public Offering
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?
March 25, 2026
Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. Th...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Supply Chain
Performance
YTD
+20.8%
+20.8%
1 Month
+3.4%
+3.4%
3 Month
+19.7%
+19.7%
6 Month
+34.5%
+34.5%
1 Year
+48.7%
+48.7%
More News
Read More
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
March 23, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout
↗
March 18, 2026
Via
Chartmill
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat
↗
February 11, 2026
Via
Chartmill
Why Is TEVA Stock Rising Pre-Market Today?
↗
January 12, 2026
Via
Stocktwits
Royalty Pharma Announces Expansion of Leadership Team
March 17, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
March 02, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 02, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
March 02, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
February 26, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
3 Healthcare Stocks Walking a Fine Line
February 18, 2026
Via
StockStory
Topics
Stocks
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call
February 18, 2026
Via
StockStory
Topics
Earnings
Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase
↗
February 14, 2026
Via
The Motley Fool
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript
↗
February 11, 2026
Via
The Motley Fool
Topics
Bonds
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
February 11, 2026
Via
StockStory
Royalty Pharma Reports Q4 and Full Year 2025 Results
February 11, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings
February 09, 2026
Via
StockStory
Topics
World Trade
3 Mid-Cap Stocks We Keep Off Our Radar
February 05, 2026
Via
StockStory
3 Profitable Stocks with Open Questions
January 20, 2026
Via
StockStory
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
January 20, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 11, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 11, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Royalty Pharma Announces Dividend Increase
January 09, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Frequently Asked Questions
Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 46.94
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 03/26/26 04:00 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 18.22B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 18B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.